Lack of association between HLA-DR2 and clinical response to methotrexate in patients with rheumatoid arthritis.
Recent studies have indicated an association between the HLA-DR2 phenotype and substantial response to methrotrexate in patients with rheumatoid arthritis (RA). To further resolve this issue, we analyzed this relationship. Our data, obtained from a multicenter, double-blind study of rigorously assessed patients with RA, demonstrated that neither HLA-DR2 nor any other HLA-DR specificity is significantly associated with a substantial clinical response to methotrexate in patients with RA.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006681:HLA-D Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis*; D015802:HLA-DR2 Antigen; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D010641:Phenotype; D012107:Research Design
D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D015802:HLA-DR2 Antigen; D008727:Methotrexate